Carnosine inhibits KRAS-mediated HCT116 proliferation by affecting ATP and ROS production

Cancer Letters

Volumn 315, Issue 2, 2012, Pages 122-128

  Iovine, Barbara ^a,b   Iannella, Maria Luigia ^a   Nocella, Francesca ^a   Pricolo, Maria Rosaria ^a   Bevilacqua, Maria Assunta ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Carnosine; Cell growth; Glycolysis; Reactive Oxygen Species

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARNOSINE; CYCLIN DEPENDENT KINASE INHIBITOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; GLYCOLYSIS; HUMAN; HUMAN CELL; KRAS GENE; MITOCHONDRION; ONCOGENE; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANTIOXIDANTS; BLOTTING, WESTERN; CARNOSINE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GLYCOLYSIS; HCT116 CELLS; HUMANS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REACTIVE OXYGEN SPECIES;

EID: 84355161424     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.021     Document Type: Article

References (27)

1. Renner C., Asperger A., Seyffarth A., Meixensberger J., Gebhardt R., Gaunitz F. Carnosine inhibits ATP production in cells from malignant glioma. Neurol. Res. 2010, 1:101-105.
2. Fontana M., Pinnen F., Lucente G., Pecci L. Prevention of peroxynitrite-dependent damage by carnosine and related sulphonamido pseudodipeptides. Cell. Mol. Life Sci. 2002, 59:546-551.
3. Guiotto A., Calderan A., Ruzza P., Borin G. Carnosine and carnosine-related antioxidants: a review. Curr. Med. Chem. 2005, 20:2293-2315.
4. Baran E.J. Metal complexes of carnosine. Biochemistry (Mosc.) 2000, 65:789-797.
5. Gallant S., Semyonova M., Yuneva M. Carnosine as a potential anti-senescence drug. Biochemistry (Mosc.) 2000, 7:866-868.
6. Babizhayev M.A., Kasus-Jacobi A. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Curr. Clin. Pharmacol. 2009, 1:4-37.
7. Shao L., Li Q.H., Tan Z. l-carnosine reduces telomere damage and shortening rate in cultured normal fibroblasts. Biochem. Biophys. Res. Commun. 2004, 324:931-936.
8. Jia H., Qi X., Fang S., Jin Y., Han X., Wang Y., Wang A., Zhou H. Carnosine inhibits high glucose-induced mesangial cell proliferation through mediating cell cycle progression. Regul. Pept. 2009, 154:69-76.
9. Renner C., Zemitzsch N., Fuchs B., Geiger K.D., Hermes M., Hengstler J., Gebhardt R., Meixensberger J., Gaunitz F. Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model. Mol. Cancer 2010, 6:92-102.
10. Buzzi N., Boland R., Russo de Boland A. Signal transduction pathways associated with ATP-induced proliferation of colon adenocarcinoma cells. Biochim. Biophys. Acta 2010, 9:946-955.
11. Robinson M.J., Cobb M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell. Biol. 1997, 2:180-186.
12. Raman M., Chen W., Cobb M.H. Differential regulation and proprieties of MAPKs. Oncogene 2007, 26:3100-3112.
13. Huynh N., Liu K.H., Baldwin G.S. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways. Biochim. Biophys. Acta 2010, 1803:1106-1113.
14. McNeil C. K-Ras mutations are changing practice in advanced colorectal cancer. J. Natl. Cancer Inst. 2008, 23:1667-1669.
15. Niault T.S., Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis 2010, 7:1165-1174.
16. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
17. Iovine B., Nino M., Irace C., Bevilacqua M.A., Monfrecola G. Ultraviolet B and A irradiation induces fibromodulin expression in human fibroblasts in vitro. Biochimie 2008, 91:364-372.
18. D'Alessio F., Mirabelli P., Gorrese M., Scalia G., Gemei M., Mariotti E., Di Noto R., Martinelli P., Fortunato G., Paladini D., Del Vecchio L. Polychromatic flow cytometry analysis of CD34+ hematopoietic stem cells in cryopreserved early preterm human cord blood samples. Cytometry A 2011, 79:14-24.
19. Ferguson W.J. The Palmer notation system and its use with personal computer applications. Br. Dent. 2005, 198:551-553.
20. Weinberg F., Hamanaka R., Wheaton W.W., Weinberg S., Joseph J., Lopez M., Kalyanaraman B., Muttlu G.M., Scott Budinger G.R., Chandal N.S. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. PNAS 2010, 107:8788-8793.
21. Samavati L., Monick M.M., Sanlioglu S., Buettner G.R., Oberley L.W., Hunninghake G.W. Mitochondrial K(ATP) channel openers activate the ERK kinase by an oxidant-dependent mechanism. Am. J. Physiol. Cell Physiol. 2002, 283:273-281.
22. Kim J., Tchernyshyov I., Semeza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic swich required for cellular adaptation to hipoxia. Cell Metab. 2006, 3:177-185.
23. Chun S.Y., Johnson C., Washburn J.G., Cruz-Correa M.R., Dang D.T., Mol L.H.Dang. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1 and HIF-2 target genes. Cancer 2010, 9:293-302.
24. Havens C.G., Ho A., Yoshioka N., Dowdy S.F. Regulation of late G1/S phase transition and APC Cdh1 by reactive oxygen species. Mol. Cell. Biol. 2006, 26:4701-4711.
25. Boldyrev A.A., Stvolinsky S.L., Fedorova T.N., Suslina Z.A. Carnosine as a natural antioxidant and geroprotector: from molecular mechanisms to clinical trials. Rejuvenation Res. 2010, 13:156-158.
26. Lee J., Lee I., Han B., Oh Park J., Jang J., Park C., Ki Kang W. Effect of Simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J. Natl. Cancer. Inst. 2011, 688:674-688.
27. Asperger A., Renner C., Menzel M., Gebhardt R., Meixensberger J., Gaunitz F. Identification of factors involved in the anti-tumor activity of carnosine on glioblastomas using a proteomics approach. Cancer Invest. 2011, 29:272-281.